U.S. Neuropathic Pain Treatment Market Overall Study Report 2024-2031 | Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Johnson & Johnson, Dr. Reddy's Laboratories Ltd

Market Overview:

Neuropathic pain is caused by damage or disease affecting the somatosensory system. Neuropathic pain drugs help in relieving pain by inhibiting sodium channels or modifying neurotransmitter level. These drugs are used to treat conditions like diabetic neuropathy, postherpetic neuralgia, etc.

Market Dynamics:

Increased R&D activities in the area of neuropathic pain treatment is expected to drive the market growth over the forecast period. Many clinical trials are being conducted to develop new and advanced treatment options. For instance, in June 2023, Novartis announced positive results from a Phase III clinical trial evaluating entrectinib for treatment of pain associated with unresectable or metastatic solid tumors and peripheral nerve sheath tumors expressing NTRK fusion proteins. Also, rising incidence of neuropathic pain conditions like diabetic neuropathy and chemotherapy-induced pain is fueling the demand for improved treatment options, thus supporting the market growth. It is estimated that over 20 million Americans suffer from diabetic peripheral neuropathy annually.

Get an Exclusive Sample Copy of the Report at: - https://www.coherentmarketinsights.com/insight/request-sample/5429

The Increase in Awareness and Diagnosis is Driving Growth in the Market

As awareness about neuropathic pain conditions and the availability of treatment options increases among patients as well as physicians, more patients are being diagnosed correctly. Physicians are better able to diagnose neuropathic pain and differentiate it from other types of pain. This is resulting in more patients seeking and receiving appropriate treatment. Research published highlighting the prevalence of neuropathic pain conditions and economic burden is also helping bring more focus on these conditions.

Growing Elderly Population is Another Key Driver

The elderly population is more susceptible to conditions that can cause neuropathic pain such as diabetes, cancer, HIV/AIDS and others. With the rising geriatric population in the U.S., the prevalence of these conditions is increasing which is expected to drive the need for neuropathic pain treatments. According to some estimates, 20% to 30% of people over the age of 65 are affected by neuropathy. As life expectancy increases, neuropathic pain due to age-related factors will continue growing as well.

Stringent Regulations and High Cost of Drug Development is a Major Restrain

The drug development and approval process for CNS drugs, especially for neuropathic pain treatment is highly regulated in U.S. due to safety concerns. Extensive research and clinical trials are required before the FDA approval. This makes the entire R&D process longer, more complex and costlier. The costs involved in drug discovery, preclinical and clinical development can exceed USD 1 billion for a single drug. Many small pharmaceutical companies find it difficult to bear these high costs which discourages research and development of new therapies. Patent expiries of blockbuster drugs is also reducing revenues which is affecting the investments in this space.

Non- pharmacological Therapies Present a Major Opportunity

While pharmacological therapies have dominated neuropathic pain treatment market so far, non-pharmacological therapies present a major opportunity going forward. Treatments such as TENS (Transcutaneous Electrical Nerve Stimulation), acupuncture, physical therapy are preferred by many patients as they avoid or minimize the side effects of medications. These alternative treatment options also allow multi-modal management of neuropathic pain. With growing desire to opt for non-opioid alternate therapies, the potential for non-drug therapies is huge in the market. Research and approval of new devices as well as combination therapies using these non-invasive approaches can be highly beneficial.

Buy This Premium Report and Get Upto 25 % OFF: https://www.coherentmarketinsights.com/insight/buy-now/5429

Combination Therapies are Emerging as a Key Trend in the Market

Combination of drug and non-drug therapies is emerging as an important trend with the objective of improving pain management. As no single treatment method provides complete relief to all patients, combining pharmacological therapies with non-pharmacological approaches seems to yield better outcomes and quality of life improvement. Some of the combinations gaining preference include use of TENS along with use of antidepressants, anti-seizure medications. Other options like acupuncture combined with topical treatments and physical therapy along with oral neuropathic pain medications are also being explored. With their synergistic pain relieving effects, combination therapies are expected to become more mainstream in the future. This trend is likely to stay and even gain adoption in the U.S. neuropathic pain treatment market.

Moreover, it will also include the opportunities available in micro markets for stakeholders to invest, a detailed analysis of the competitive landscape, and product services of key players. Analysis of U.S. Neuropathic Pain Treatment companies, key tactics followed by Leading Key Players:

◘ Teva Pharmaceutical Industries Ltd.
◘ Eli Lilly and Company
◘ Johnson & Johnson
◘ Dr. Reddy's Laboratories Ltd.
◘ Pfizer Inc.
◘ Cipla Inc.
◘ Lupin Limited
◘ Averitas Pharma Inc.
◘ NeuroBo Pharmaceuticals Inc.
◘ LEXICON PHARMACEUTICALS INC.
◘ Asahi Kasei Corporation
◘ Vertex Pharmaceuticals Incorporated
◘ Biogen

Note: Major Players are sorted in no particular order.

By Drug Type: (Pain Relievers (NSAIDS, Opioids (Oxycodone, and Others)), Anti-seizure Medications (Gabapentin, Pregabalin, and Others), Topical Treatments, Antidepressants (Duloxetine, Amitriptyline, Escitalopram, and Others), and Others)

By Indication: (Diabetic Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy, Idiopathic Peripheral Neuropathy, and Others)

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

The Study Objectives are:

A comprehensive insight into key players operating in the U.S. Neuropathic Pain Treatment Market and their corresponding data.
It includes product portfolio, annual revenue, expenditure on research and development, geographical presence, key developments in recent years, and growth strategies.
Regional analysis, which includes insight into the dominant market and corresponding market share.
It also includes various socio-economic factors affecting the evolution of the market in the region.
The report offers a comprehensive insight into different individuals from value chains such as raw materials suppliers, distributors, and stockholders.
Table of Contents:

Market scenario 2023

Chapter 1: Introduction, Market Driving Force Product Objective of Study and Research Scope the U.S. Neuropathic Pain Treatment market
Chapter 2: Exclusive Summary - the basic information of the U.S. Neuropathic Pain Treatment Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends, and Challenges & Opportunities of the U.S. Neuropathic Pain Treatment
Chapter 4: Presenting the U.S. Neuropathic Pain Treatment Market Factor Analysis, Supply/Value Chain, PESTEL analysis, Market Entry, and Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User, and Region/Country 2023 - 2030
Chapter 6: Evaluating the leading manufacturers of the U.S. Neuropathic Pain Treatment market which consists of its Competitive Landscape, Peer Group Analysis, Market positioning & Company Profile
Chapter 7: To evaluate the market by segments, by countries, and by Manufacturers/Companies with revenue share and sales by key countries in these various regions (2023-2030)
Chapters 8 & 9: Displaying the Appendix, Methodology, and Data Source

We Offer Customized Report, Click @ https://www.coherentmarketinsights.com/insight/request-customization/5429

Key Questions Answered:

What is the market size and CAGR of the U.S. Neuropathic Pain Treatment Market during the forecast period?
How is the growing demand impacting the growth of U.S. Neuropathic Pain Treatment Market shares?
What is the growing demand of the Market during the forecast period?
Who are the leading vendors in the market and what are their market shares?
What is the impact of the COVID-19 pandemic on the APAC U.S. Neuropathic Pain Treatment Market?

Contact Us

Mr. Shah
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400, Burlingame,
CA 94010, United States
Phone: US +12067016702 / UK +4402081334027
JAPAN:+81-50-5539-1737
INDIA:+91-848-285-0837
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

This release was published on openPR.